A study to access the immunohistochemical expression of PD-L1, PD-1, and CTLA-4 in patients with advanced stage melanoma
Latest Information Update: 08 Dec 2021
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 08 Dec 2021 New trial record